Zomedica ( (ZOMDF) ) has issued an announcement.
Zomedica reported record revenue of $7.9 million for the fourth quarter and $27.3 million for the full year 2024, with a 70% gross margin and $71 million in liquidity to support growth. The company experienced a transformative year, driven by strong performance in its diagnostics segment and strategic expansions, positioning itself for accelerated growth in 2025 through new product launches and international market expansion.
More about Zomedica
Zomedica is a veterinary health company that provides point-of-care diagnostic and therapeutic products for equine and companion animals. The company focuses on innovative solutions in the veterinary industry, with a significant emphasis on diagnostics and therapeutics, including products like TRUFORMA and VETGuardian.
YTD Price Performance: -75.00%
Average Trading Volume: 8,529,049
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $38.22M
See more insights into ZOMDF stock on TipRanks’ Stock Analysis page.